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In vitro anti-malarial interaction 
and gametocytocidal activity of cryptolepine
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Dalu Mancama3 and Colin W. Wright4
Abstract 
Background: Discovery of novel gametocytocidal molecules is a major pharmacological strategy in the elimination 
and eradication of malaria. The high patronage of the aqueous root extract of the popular West African anti-malarial 
plant Cryptolepis sanguinolenta (Periplocaceae) in traditional and hospital settings in Ghana has directed this study 
investigating the gametocytocidal activity of the plant and its major alkaloid, cryptolepine. This study also investigates 
the anti-malarial interaction of cryptolepine with standard anti-malarials, as the search for new anti-malarial combina-
tions continues.
Methods: The resazurin-based assay was employed in evaluating the gametocytocidal properties of C. sanguinolenta 
and cryptolepine against the late stage (IV/V) gametocytes of Plasmodium falciparum (NF54). A fixed ratio method 
based on the SYBR Green I fluorescence-based assay was used to build isobolograms from a combination of cryptole-
pine with four standard anti-malarial drugs in vitro using the chloroquine sensitive strain 3D7.
Results: Cryptolepis sanguinolenta  (IC50 = 49.65 nM) and its major alkaloid, cryptolepine  (IC50 = 1965 nM), showed 
high inhibitory activity against the late stage gametocytes of P. falciparum (NF54). In the interaction assays in asex-
ual stage, cryptolepine showed an additive effect with both lumefantrine and chloroquine with mean ΣFIC50s of 
1.017 ± 0.06 and 1.465 ± 0.17, respectively. Cryptolepine combination with amodiaquine at therapeutically relevant 
concentration ratios showed a synergistic effect (mean ΣFIC50 = 0.287 ± 0.10) whereas an antagonistic activity (mean 
ΣFIC50 = 4.182 ± 0.99) was seen with mefloquine.
Conclusions: The findings of this study shed light on the high gametocytocidal properties of C. sanguinolenta and 
cryptolepine attributing their potent anti-malarial activity mainly to their effect on both the sexual and asexual stages 
of the parasite. Amodiaquine is a potential drug partner for cryptolepine in the development of novel fixed dose 
combinations.
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Background
Malaria still remains a disease of public health impor-
tance with an estimated 3.3 billion people at risk globally 
and 214 million new cases with 438,000 deaths reported 
in 2015. The sub-Saharan region of Africa accounts for an 
estimated 90% of all deaths due to malaria, with children 
under 5 years of age accounting for 78% of these [1].
Despite the successes seen in the approach to reduce 
the number of deaths associated with malaria, this dis-
ease still remains a grave public health problem. The 
majority of the currently used anti-malarial drugs were 
intended to target the symptom-causing pathogenic 
blood stages in man and to contend with the continu-
ous risk of drug resistance [2]. Nonetheless, to achieve 
the global objective of malaria eradication, medicines 
with activity against parasite transmission [3] and the 
hepatic stages responsible for disease relapse also need to 
be developed. The reported development of Plasmodium 
falciparum resistance to the most potent anti-malarial 
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agents (the artemisinins) in the Thai–Cambodia border 
puts the progress achieved under serious threat [4, 5]. 
This scenario requires the urgent need to accelerate the 
discovery and development of novel anti-malarial leads 
and combinations that have activity against both the sex-
ual and asexual stages of the parasite.
For this reason, the popular West African anti-malar-
ial plant Cryptolepis sanguinolenta (Periplocaceae) and 
it major alkaloid, cryptolepine were assessed against the 
transmissible stages of the human malaria parasite. The 
aqueous root extract of C. sanguinolenta has been used 
for decades in West Africa for the treatment of malaria 
[6] and currently, several herbal preparations registered 
for use in Ghanaian orthodox clinics contain the aque-
ous root extract of the plant. The wide usage of the plant 
may be attributed to the safety and high cure rate of a tea 
bag formulation (Phyto-laria) of the plant against chloro-
quine resistant strains of P. falciparum in human clinical 
trials [7], supporting their usage as alternative tools to the 
standard anti-malarial interventions or as complemen-
tary treatments in the absence of standard anti-malarial 
drugs. Cryptolepine, the major indoloquinoline alkaloid 
isolated from the plant has the most potent antiplasmo-
dial activity [8] and has been shown to exhibit potent 
in vitro activities against both chloroquine-sensitive and 
chloroquine-resistant P. falciparum [9].
With lessons learnt from the widely used artemisinin 
derivatives, thus their isolation from the medicinal plant 
Artemisia annua, directed the exploration of the popu-
larly used anti-malarial plant, C. sanguinolenta and its 
major alkaloid, cryptolepine for possible gametocytocidal 
effects on P. falciparum. The in vitro anti-malarial inter-
action of cryptolepine with chloroquine, lumefantrine, 
amodiaquine and mefloquine (Fig.  1) were also ascer-
tained in this study.
Methods
Plant material
The sun-dried cut roots of C. sanguinolenta used in this 
study were collected at the Centre for Scientific Research 
into Plant Medicine (CSRPM), Mampong-Akwapim, 
Ghana in August 2012 and were identified by the Plant 
Development Centre of the Institution. Its authenticity 
was confirmed by Dr. Kofi Annan of the Department of 
Pharmacognosy, KNUST and subsequently compared 
to a voucher specimen KNUST/HM1/2008/L056 at the 
herbarium of the Department of Pharmacognosy/Herbal 
Medicine, College of Health Sciences.
The powdered roots (650  g) were boiled for 30  min 
with 5  L of distilled water, decanted and filtered. The 
filtrate was freeze dried to obtain a freeze-dried sam-
ple of the crude extract (yield = 11.08% w/w) referred 
to as cryptolepis (CPS). Cryptolepis was reconstituted 
in distilled water prior to use in the gametocytocidal 
assay.
Drugs/chemicals
Lumefantrine, chloroquine, mefloquine and amodi-
aquine were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). Gentamicin was obtained from Invitrogen 
Life Technologies Inc. (Carlsbad, CA, USA). RPMI-
1640 medium, streptomycin/penicillin, l-glutamine and 
HEPES were obtained from Gibco BRL Life Technologies 
(Grand Island, NY, USA). Cryptolepine hydrochloride 
(purity 98.9%) was isolated from the root of C. sanguino-
lenta as described by Kuntworbe et al. [10].
In vitro cultivation of asexual stage Plasmodium falciparum
The in  vitro cultivation method of P. falciparum drug-
sensitive strain NF54 was adapted from Reader et al. [11]. 
Parasite cultures were maintained in human erythrocytes 
(5% haematocrit, A rhesus positive) suspended in com-
plete parasite medium (CPM) (RPMI 1640 medium sup-
plemented with 25  mM HEPES, 0.2% d-glucose, 24  μg/
mL gentamicin, 0.2% sodium bicarbonate (pH  =  7.3), 
200 μM hypoxanthine with 10% human serum (A rhesus 
positive) and flushed with 90%  N2, 5%  O2, and 5%  CO2 in 
humidified modular chambers at 37 °C. Parasite medium 
was changed daily and fresh CPM introduced. Parasitae-
mia of Giemsa-stained slides were monitored daily with 
light microscopy.
Induction of gametocytogenesis and maintenance 
of gametocyte cultures
Combined conditions of low haematocrit and nutri-
ent starvation were employed in the induction of game-
tocytogenesis. To trigger gametocytogenesis, asexual 
cultures of 6–10% parasitaemia were diluted to 0.5% 
parasitaemia at 6% haematocrit and then introduced into 
a glucose-free medium. The medium was kept at 37  °C 
gassed with 90%  N2, 5%  O2, and 5%  CO2 without shaking. 
The medium was changed daily. After 72 h, the haema-
tocrit was dropped to 3% (day 0). Gametocytogenesis 
was monitored daily before medium (glucose-free) was 
changed. To eliminate residual asexual parasites, cultures 
were treated on days 6–9 by continuous treatment with 
50  mM N-acetyl glucosamine (NAG). The medium was 
then fortified with 0.2% glucose from day 10 onwards. 
The gametocyte levels were monitored daily by micros-
copy until they were predominantly (> 90%) stage V and 
these gametocytes were employed in the resazurin-based 
assay.
Gametocyte viability assays
The in  vitro gametocytocidal activities of cryptolepine 
and the aqueous root extract of C. sanguinolenta were 
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measured by assessing gametocyte survival after drug 
exposure using resazurin-based assay. The resazurin-
based assay was based on method described by Tanaka 
et  al. [12]. Eleven drug concentrations of cryptolepine, 
the aqueous root extract of C. sanguinolenta and dihy-
droartemisinin ranging from 10 µM to 1.69 ×  10−4 µM 
(threefold serial dilutions) prepared in distilled water 
were placed in triplicate in a transparent 96-well flat 
bottom plates. Parasitized RBCs were added to a final 
concentration of 5% haematocrit, 2% gametocytaemia in 
a total incubation volume of 100 µL.
Dihydroartemisinin (10  µM) was used as a reference 
standard in the drug assay. The drug plate was placed on a 
mechanical shaker for 20 s before being encased in an air-
tight chamber and gassed for 5 min with a 5%  O2, 5%  CO2 
and a balanced  N2 mixture. The plates were incubated at 
37 °C for 48 h after which 10 µL of resazurin-based assay 
reagent was added to each well and the plate was shaken 
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Fig. 1 Structure of anti-malarial agents used in the interaction assay. a Mefloquine, b amodiaquine, c chloroquine, d lumefantrine, e crytolepine 
hydrochloride
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for 20 s. The plate was left to incubate for 2 h and then 
centrifuged at 120×g for 1 min. The supernatant (70 µL) 
was transferred to a clean 96-well plate before being read 
in a multiwell spectrophotometer (Infinite F500, Tecan, 
USA) by fluorescence detection at 535/612 nm. Gameto-
cyte survival in each test culture after treatment was cal-
culated relative to the control wells. The experiment was 
performed in triplicate on two separate occasions.
Antiplasmodial interaction assay
In vitro malaria parasite cultivation
Plasmodium falciparum laboratory strain 3D7 was cul-
tured according to method described by Trager and 
Jensen [13] with slight modifications as described. Human 
erythrocytes (O rhesus positive) fortified in complete 
culture medium (pH 7.3) served as host cells for parasite 
maturation. The complete culture medium consisted of 
filter-sterilized RPMI 1640 solution supplemented with 
0.5% AlbuMAX II, 0.72% HEPES (N-2-hydroxyethyl-
piperazine-N-2-ethanesulfonic acid) and hypoxanthine 
buffered with 0.4% sodium bicarbonate  (NaHCO3). Gen-
tamicin (0.005 mg/mL) was added to the final solution.
A controlled experimental environment with a gas 
supply of 92%  N2, 5%  CO2 and 3%  O2 at 37 °C was used 
to grow the parasites in culture flasks. Parasite growth, 
viability and stages were monitored daily by light micros-
copy of Giemsa-stained cultures after changing the cul-
ture media. Parasitaemia levels were kept between 2 and 
8%, with a 5% haematocrit.
In vitro antiplasmodial interaction assay
The SYBR Green I-based fluorescence assay was 
employed to investigate the in  vitro anti-malarial inter-
action between cryptolepine and the four standard 
anti-malarial agents against P. falciparum (chloroquine 
sensitive, 3D7). Cryptolepine (Drug A, CPE), lumefan-
trine (LUM), mefloquine (MFQ), chloroquine (CQ) and 
amodiaquine (AMQ) stock solutions were prepared in 
ethanol at 1  mM. Concentrations ranging from 32.5 to 
2080 nM for CPE, 2 to 640 nM for LUM, 3.2 to 83 nM 
for CQ, 5 to 800 nM for MFQ and 1 to 128 nM for AMQ 
were used for the interaction assays. A fixed ratio interac-
tion assay as described previously by Fivelman et al. [14] 
was employed in this assay.
For each assay, fixed drug ratios (4:1, 3:2, 2:3 and 1:4) 
were prepared in a 10 µL volume for cryptolepine (Drug 
A) and any of the standard agents (Drug B). A twofold 
serial dilution followed each fixed ratio in a well ensur-
ing the  IC50 of each drug alone (5:0 and 0:5) fell approxi-
mately at the mid-point of the serial dilution. Parasite 
culture (90  µL) was added to each well to obtain seven 
desired final concentrations for the assay. The final haem-
atocrit and parasitaemia of the culture media were 2 and 
1%, respectively. The assay plates were gassed with a mix-
ture of gases containing 92%  N2, 5%  CO2 and 3%  O2 for 
6 min and carefully arranged in a modular incubator (Bil-
lups-Rothenberg Inc, USA). The plates were incubated 
at 37 °C for 48 h. Post incubation, the plates were stored 
at −  30  °C wrapped in aluminium foil. The plates were 
thawed and subsequently mixed with 100 μL of Malaria 
SYBR Green 1 fluorescent (MSF) lysis buffer containing 
SYBR Green. The plates were incubated at room tem-
perature in the dark for an hour and fluorescence data 
(relative fluorescence unit, RFU) were acquired using a 
fluorescence multi-well plate reader (Tecan Infinite M200 
Pro) with emission and excitation wavelength at 535 and 
485 nm, respectively. The experiment was performed in 
triplicate.
Statistical analysis
The performance of the gametocyte assay was assessed 
by estimating the Z factor statistical parameter described 
by Zhang et al. [15]. Gametocyte viability was calculated 
using the relation below 
The  IC50 (50% inhibitory concentration) served as a 
measure of anti-malarial activity and was determined 
by plotting and analysing dose–response curves using 
GraphPad Prism (GraphPad 6 Software, San Diego, 
USA). The assessment of drug interaction was based on 
calculating the sum of the fractional inhibitory concen-
tration (ΣFIC50s) at the given effective concentration by 
the formula below
The nature of interaction was explained using ΣFIC50s. 
Values <  0.8 denote synergism, 0.8–1.4 denotes addi-
tive interaction, and ≥ 1.4 denotes antagonism [16]. The 
overall nature of the anti-malarial interaction was based 
on the mean ΣFIC50s.
A Microsoft Excel datasheet was used to calculate 
percentage inhibition in relation to the control results. 
Figures were made using GraphPad Prism for Windows 
version 6.0 (GraphPad Software, San Diego, CA, USA).
% Parasite viability
=
(
Fluorescencecompound −Meanfluorescencebackground
)
(
Meanfluorescencepositive −Meanfluorescencebackground
) × 100
∑
FIC50 =
(
IC50 of cryptolepine in combination
IC50 of cryptolepine alone
)
+
(
IC50 of Drug B in combination
IC50 of Drug B alone
)
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Results
Gametocyte viability assay
Data from the late stage gametocyte assay indicates a 
preferential inhibition of the viability of mature sexual-
stage parasites by the aqueous extract of C. sanguino-
lenta and its major alkaloid cryptolepine. The reduction 
in gametocytes was in a dose-dependent fashion in all 
drug treatments and statistically significant.  IC50 values 
of 49.65 and 1965 nM were recorded for CPS and CPE, 
respectively (Fig. 2). The Z-factor for the assay was calcu-
lated to be 0.98, indicating that the assay performed very 
well. Cryptolepis sanguinolenta however, demonstrated 
more potent activity against the late stage gametocytes 
compared to its major alkaloid, cryptolepine. The refer-
ence standard, dihydroartemisinin (10–1.69 × 10−4 µM) 
exhibited an  IC50 of 15  nM (Fig.  2) falling within the 
range normally expected for the resazurin-based assay 
and other gametocytocidal assay platforms, as described 
by Reader et al. [11].
Taken together, C. sanguinolenta (CPS) and it major 
alkaloid, cryptolepine (CPE) have potent inhibitory 
effects on the late stage gametocyte of P. falciparum 
strain NF54 (Fig. 2).
In vitro antiplasmodial interaction
The in vitro  IC50s of cryptolepine and the standard anti-
malarial drugs in the asexual stages of P. falciparum 
3D7 are presented in Table 1. In the in vitro interaction 
assays, cryptolepine’s combination with chloroquine or 
lumefantrine showed additivity with a mean ΣFIC50 of 
1.342  ±  0.34 and 1.017  ±  0.45, respectively (Table  2). 
Cryptolepine combination with amodiaquine at all 
therapeutically relevant ratios showed a mean ΣFIC50 
(0.235  ±  0.15) of less than 0.8 suggesting synergism. 
Antagonism (mean ΣFIC50 = 4.182 ± 0.68) was observed 
when cryptolepine was combined with mefloquine. 
Isobolograms indicating various cryptolepine-based 
combinations are presented in Fig. 3.
Discussion
The aqueous root extract of C. sanguinolenta has gained 
wide usage as an anti-malarial agent in both herbal and 
orthodox hospitals in Ghana and other West African 
countries. This coupled with the plant’s established effi-
cacy against the asexual stages of P. falciparum [7, 17] 
motivated this study to evaluate possible gametocyto-
cidal properties of the plant and its major alkaloid, cryp-
tolepine. In the current study, the stage-specific in vitro 
gametocytocidal activities of C. sanguinolenta (CPS) 
and its major alkaloid cryptolepine (CPE) were tested 
against the late-stage NF54 strain of the malaria parasite, 
P. falciparum. The assay assesses gametocyte survival 
after drug exposure using resazurin-based assay, and 
indicated a potent loss of viability of the late stage game-
tocyte with both C. sanguinolenta (49.65 nM) and cryp-
tolepine (1965 nM). This result is not surprising as earlier 
work [18] demonstrated potent in  vitro loss of viability 
of the late stage gametocytes by local polyherbal anti-
malarial products containing C. sanguinolenta. Despite 
the demonstrated activity, the major alkaloid from the 
plant known to possess the most efficacious in  vitro 
antiplasmodial activity showed less gametocytocidal 
activity compared to the root extract of the plant. This 
indicates the presence of other alkaloids in the aqueous 
root extract of the plant contributing to the high activity 
against gametocytes. Given the demonstrated high game-
tocytocidal properties of CPS and CPE, their prominent 
antiprotozoal activity may be attributed mainly to their 
effect on both the asexual and sexual stages of the Plas-
modium parasite.
Our current study also sheds light on the in vitro anti-
malarial interaction of cryptolepine with four standard 
anti-malarial agents. The steady rise in the resistance of 
P. falciparum to current anti-malarial drugs, has directed 
current therapeutic strategies toward the development of 
combination therapies. Cryptolepine is a promising anti-
malarial compound effective against both chloroquine-
sensitive and chloroquine-resistant P. falciparum [9]. 
It has however been shown to possess DNA intercalat-
ing and topoisomerase II inhibitory effect [19, 20]. This 
has directed research into structural modification of the 
compound to synthesize relatively safer derivatives. Pre-
vious pharmacokinetic reports of cryptolepine showed a 
rapid disappearance from the plasma and localization in 
various tissues except the CNS with possible hepatobil-
iary clearance pathway [21]. Aldehyde oxidase has been 
shown to be involved in the metabolism of cryptolepine 
[22]. Nanoformulation of cryptolepine hydrochloride 
demonstrated a better in  vivo antiplasmodial chemo-
suppression, superior bioavailability and an increased 
half-life compared with the free compound [23]. A can-
didate drug partner is sought for the parallel develop-
ment of cryptolepine, comparable to ACT encouraged 
by the WHO. This approach will provide cryptolepine 
with potential drug partners for further development to 
reduce the risk of drug resistance to P. falciparum. A new 
anti-malarial combination should preferably target both 
the rapidly replicating asexual stages and the less meta-
bolically active, nonreplicating mature gametocytes.
The in  vitro anti-malarial interaction of cryptole-
pine using the SYBR Green fluorescent assay demon-
strated varied interaction with these standard agents. 
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Fig. 2 Gametocyte viability of CPS and CPE. Gametocytocidal activity of CPS (a), CPE (b) and DHA (c) against late stage gametocytes. Bars represent 
mean gametocyte activity at each compound concentration (with standard deviation [SD])
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Cryptolepine showed varied interaction with the 4-ami-
noquinolines, amodiaquine and chloroquine. The 
combination of cryptolepine with amodiaquine had a 
synergistic effect in  vitro (mean ΣFIC  =  0.235  ±  0.15) 
whereas an additive effect (mean ΣFIC =  1.342 ±  0.34) 
was seen with chloroquine. The 4-aminoquinolines 
are considered to share, in principle, the same mode of 
action. However, a different interactive profile was found 
with cryptolepine. It is therefore wrong to equate amo-
diaquine to chloroquine in terms of activity. The synergy 
observed with amodiaquine may be due to the Man-
nich base structure in amodiaquine. A similar synergis-
tic effect attributed to the Mannich base side chain in 
pyronaridine and amodiaquine has been reported with 
artemisinin [24]. An antagonistic effect was observed 
when cryptolepine was combined with mefloquine. 
Mefloquine has been shown to inhibit the uptake of chlo-
roquine as well as chloroquine’s ability to cause the accu-
mulation of undigested haemoglobin [25].
Mefloquine (and possibly quinine) has also been 
hypothesized to inhibit endocytosis of the erythrocyte 
cytosol by the parasite, resulting in a lowered free haem 
concentration, to which chloroquine binds, in the diges-
tive vacuole [25]. Cryptolepine, an indoloquinoline has 
been shown to act similarly to chloroquine by inhibit-
ing the biomineralization of the toxic waste material 
haem into an insoluble complex, haemozoin, leading to 
membrane damage and parasite death [9, 26, 27]. On 
this background it is not surprising that antagonism was 
observed when cryptolepine was combined with meflo-
quine, possibly following a similar pathway of antago-
nism demonstrated by mefloquine when combined with 
chloroquine. In the case of cryptolepine-lumefantrine 
combination at therapeutically relevant concentration 
ratios, an additivity effect (mean ΣFIC =  1.017 ±  0.45) 
was observed.
The combination of cryptolepine with amodiaquine 
showed synergy in vitro in P. falciparum strain 3D7 and 
this combination provides a dual action with both agents 
inhibiting haemoglobin digestion in the asexual blood 
stages and amodiaquine inhibiting gametocyte matu-
ration/gamete exflagellation by different mechanisms 
[28]. Such combinations with dual action are relevant in 
malaria endemic regions, where infections are usually 
asymptomatic with clinical symptoms developing late 
in the course of the disease, permitting the maturation 
of gametocytes and hence disease transmission [29, 30]. 
The enhanced anti-malarial activity of cryptolepine with 
amodiaquine may possibly result in low-dose treatment 
regimens and hence reduce toxicity. However, it should 
be noted that these assay results may vary in different 
plasmodium strains and further investigations is recom-
mended in the early stages of gametocytes and in several 
P. falciparum strains and/or rodent malaria models to 
accentuate the interactions established.
Conclusions
Cryptolepis sanguinolenta and its major alkaloid, cryp-
tolepine exhibited high activities against the late-stage 
gametocyte of P. falciparum NF54, attributing their pri-
mary targets as the mature gametocytes and intraeryth-
rocytic parasite. Lumefantrine and chloroquine both 
showed additivity when each drug was combined with 
cryptolepine whereas antagonism was observed when 
cryptolepine was combined with mefloquine at thera-
peutically relevant concentration ratios. Cryptolepine 
in combination with the Mannich base, amodiaquine, 
Table 1 In vitro anti-malarial activity against asexual 
blood stages
IC50 values of cryptolepine, lumefantrine, mefloquine, and chloroquine against 
Plasmodium falciparum strain 3D7 are expressed as mean ± standard error of 
mean of the results of at least three independent assays
Drugs Mean  IC50 ± S.E.M (nM)
Amodiaquine 12.63 ± 1.66
Mefloquine 12.98 ± 0.47
Lumefantrine 10.80 ± 0.97
Chloroquine 11.05 ± 1.79
Cryptolepine 603.82 ± 75.57
Table 2 In vitro interaction of cryptolepine combinations against 3D7 P. falciparum strains
The ratios 4:1, 3:2, 2:3 and 1:4 refer to fixed dosage ratios for drug A (cryptolepine) to drug B (amodiaquine, mefloquine, lumefantrine, chloroquine). Values are the 
means from ≥ 3 experiments
Drug combination ΣFIC50 Mean ΣFIC50 Interaction
4:1 3:2 2:3 1:4
Cryptolepine + amodiaquine 0.640 ± 0.08 0.0234 ± 0.11 0.0631 ± 0.07 0.421 ± 0.12 0.287 ± 0.10 Synergism
Cryptolepine + mefloquine 3.015 ± 0.91 3.013 ± 1.01 5.106 ± 1.13 5.595 ± 0.91 4.182 ± 0.99 Antagonism
Cryptolepine + lumefantrine 2.1108 ± 0.17 1.6865 ± 0.01 0.1475 ± 0.02 0.1245 ± 0.04 1.017 ± 0.06 Additivity
Cryptolepine + chloroquine 1.95 ± 0.21 1.775 ± 0.36 1.66 ± 0.04 0.475 ± 0.05 1.465 ± 0.17 Additivity
Page 8 of 9Forkuo et al. Malar J  (2017) 16:496 
showed synergism. On this basis, the cryptolepine–
amodiaquine combination certainly deserves atten-
tion for further studies in regards to the synergy 
demonstrated.
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